Bon Secours Mercy Health Nears $6 Billion Takeover of Bain-Backed Surgery Partners

The Quick Take

• Bon Secours Mercy Health, a major US not-for-profit hospital chain, is nearing a $6 billion takeover of Surgery Partners, a Bain Capital-backed ambulatory surgery centre operator.
• The deal would represent the largest transaction in the US ambulatory surgery centre space and reflects hospitals' urgent strategic shift toward outpatient care.
• Surgery Partners stock surged on the news, with SGRY shareholders pricing in the acquisition premium ahead of formal deal announcement.

Bon Secours Mercy Health, one of the largest not-for-profit health systems in the United States, is reportedly in late-stage negotiations to acquire Surgery Partners (SGRY), a portfolio company backed by Bain Capital. The proposed transaction is valued at approximately $6 billion and represents a significant acceleration in the ongoing structural shift of US healthcare delivery from high-cost inpatient hospital settings toward outpatient and ambulatory surgical facilities. Not-for-profit health systems have become increasingly aggressive acquirers of ambulatory surgery centres as payers — including CMS and commercial insurers — continue to redirect patients and reimbursements toward lower-cost outpatient settings where clinical outcomes are comparable.

A $6 billion transaction of this scale will reshape the competitive landscape for ambulatory surgery operators. Surgery Partners operates hundreds of facilities across the US, and integration with Bon Secours' physician network would create a vertically integrated outpatient system capable of capturing the full surgical care continuum. Publicly traded ambulatory and outpatient surgery peers — including Tenet Healthcare's USPI division and AmSurg — face increased competition from a scaled not-for-profit player. Private equity firms that own surgical facility assets may see valuation uplift as the deal sets a pricing benchmark. Bain Capital exits at a significant multiple, validating private equity's thesis that ambulatory surgery centres command premium valuations in a healthcare consolidation cycle.

The pivotal signal is SGRY's official confirmation of a signed merger agreement and the specific per-share consideration, which will determine the final acquisition premium for shareholders. Regulatory review by the FTC's healthcare division is a key risk given recent antitrust scrutiny of hospital mergers — particularly transactions involving large not-for-profit systems. The macro determinant of deal success is CMS reimbursement policy for ambulatory surgery centres in the 2027 rate cycle; higher outpatient rates would confirm the strategic rationale and potentially trigger competing bids. Monitor the timeline for HSR filing, board approvals, and Bain Capital's exit structure.

Synthesized from 1 source.